News
Shares of Novo Nordisk are trading lower Wednesday morning. The stock is extending a dramatic sell-off from Tuesday's session ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...
The pharmaceutical giant cut its guidance and said U.S. sales of Ozempic grew more slowly.
Novo Nordisk downgraded to Buy amid guidance cuts & competition. Explore its long-term obesity drug potential, strong ...
Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...
Now, it’s worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for ...
For the healthcare stock to reach $1 trillion by 2030, shares of Novo Nordisk would need to rise by approximately 120% in the span of six years. That would mean, on average, the stock would ...
With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...
Novo Nordisk stock drops 20%, but strong fundamentals, growth segments, and R&D pipeline make it an undervalued opportunity.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback